Ryan Sato, MD
Dermatology · Honolulu, HINPI 1235443995
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $140,159 of the $225,564 with a category attached, or 62.1%. 26 manufacturers reported payments, led by LEO Pharma Inc. at 33.4% of the total. 2025 is the largest year on record at $144,607, more than ten times the $1,366 reported in 2019. Among dermatology clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,087 payments — averaging $207.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- LEO Pharma Inc.$75K
- Galderma Laboratories, L.p.$37K
- Pfizer$33K
- Organon$28K
- Lilly USA, LLC$16K
- E.r. Squibb & Sons, L.L.C.$14K
- plus $22K from 20 others
What the payments were for
- Consulting fees$39,40917%
- Speaking & faculty fees$140,15962%
- Travel & lodging$20,1919%
- Food & beverage$25,07511%
- Education$7290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| LEO Pharma Inc. | 186 | $75,354 |
| Galderma Laboratories, L.p. | 91 | $37,250 |
| Pfizer | 52 | $33,148 |
| Organon | 34 | $27,565 |
| Lilly USA, LLC | 77 | $16,170 |
| E.r. Squibb & Sons, L.L.C. | 73 | $13,700 |
| AbbVie(2 entities) | 165 | $5,593 |
| Sanofi | 60 | $4,806 |
| Dermavant Sciences, Inc. | 11 | $3,323 |
| Regeneron Healthcare Solutions, Inc. | 46 | $1,686 |
| Sun Pharmaceutical Industries Inc. | 58 | $1,302 |
| Amgen | 56 | $1,237 |
| Novartis | 53 | $784 |
| Array Biopharma Inc | 1 | $720 |
| Incyte Corporation | 38 | $719 |
| Arcutis Biotherapeutics, Inc. | 24 | $612 |
| Johnson & Johnson | 23 | $490 |
| UCB, Inc. | 17 | $464 |
| Sanofi-aventis U.S. LLC | 3 | $260 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 8 | $142 |
| Dermira, Inc. | 3 | $62 |
| Merz North America, Inc. | 2 | $58 |
| Kyowa Kirin, Inc. | 2 | $45 |
| Bristol Myers Squibb | 2 | $41 |
| VYNE Pharmaceuticals Inc. | 1 | $23 |
| Almirall LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$225,564 in reported general payments places this provider in the 90th percentile of 67 dermatology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 44 | $188,280 |
| Taltz AutoinjectorIxekizumab | 23 | $181,494 |
| Dupixent SyringeDupilumab | 15 | $57,101 |
| Tacrolimus | 161 | $51,469 |
| EucrisaCrisaborole | 18 | $13,546 |
| Betamethasone Dipropionate | 186 | $8,843 |
| Pimecrolimus | 18 | $7,104 |
| Desonide | 70 | $5,130 |
| Triamcinolone Acetonide | 361 | $4,042 |
| Halobetasol Propionate | 72 | $2,838 |
| Doxycycline Monohydrate | 46 | $2,678 |
| Clobetasol Propionate | 48 | $2,038 |
| Clindamycin Phosphate | 50 | $1,964 |
| Ketoconazole | 93 | $1,909 |
| Calcipotriene | 12 | $1,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEucrisa | $33,148 | $13,54618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 67 dermatology providers in Hawaii.
Other dermatology in Honolulu
- Sarah HowellHonolulu$653K
- Douglas JohnsonHonolulu$568K
- Greg SakamotoHonolulu$20K
- Kory KitagawaHonolulu$18K
- Kevin DawsonHonolulu$16K
- Dylan LeeHonolulu$15K
- Sarah GrekinHonolulu$13K
- Gregory HerbichHonolulu$12K
- Stella MatsudaHonolulu$9K
- Aaron FongHonolulu$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.